Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer

Published:2015-03-19 Issue:7 Volume:4 Page:e1014242
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

de Goeje Pauline L,Bezemer Koen,Heuvers Marlies E,Dingemans Anne-Marie C,Groen Harry Jm,Smit Egbert F,Hoogsteden Henk C,Hendriks Rudi W,Aerts Joachim Gjv,Hegmans Joost Pjj

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1014242

Reference39 articles.

1. The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer

2. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment

3. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients

4. Myeloid-Derived Suppressor Cells in the Development of Lung Cancer

5. Complexity and challenges in defining myeloid-derived suppressor cells

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. LILRB4 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target;Chinese Medical Journal;2024-07-08

3. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway;Journal of Experimental & Clinical Cancer Research;2024-07-01

4. Disruption of Circadian Clock Induces Abnormal Mammary Morphology and Aggressive Basal Tumorigenesis by Enhancing LILRB4 Signaling;2024-03-20

5. LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets;Biomolecules;2024-02-04